Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | -18.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.17 | N/A | -18.06% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized the importance of their current initiatives but did not offer specific expectations for future performance.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on ongoing projects and strategic partnerships.
Despite missing on EPS, Halozyme's stock rose significantly by 18.68% following the earnings report. This increase may reflect investor optimism about the company's ongoing projects and potential future developments, despite the lack of specific guidance. The market appears to be focusing on long-term growth prospects rather than short-term earnings results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
INTERCONTINENTAL EXC
Nov 5, 2013